Pediatric covid-19 2025-2026
Closed Solicitation Posted
- Solicitation number
- 75D30125R00116
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Georgia 30341, United States
- Points of contact
-
- Brian Swann qty0@cdc.gov
- James Sprigler zbs6@cdc.gov (404) 498-3879
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) is seeking to award contracts to manufacturers of U.S.-licensed or authorized pediatric COVID-19 vaccines for the 2025-2026 period through an Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The solicitation supports the Vaccine for Children (VFC) program, which provides federal support for purchasing vaccines for eligible children, including Medicaid recipients, uninsured children, American Indian/Alaska Native children, and those with insurance that does not cover vaccine costs. Offerors must be pediatric vaccine manufacturers in accordance with 42 U.S.C. 1396s, with the ability to provide vaccines with a minimum 12-month shelf life. Evaluation criteria will focus on technical capabilities, pricing, and past performance of the manufacturers. Proposals are due by 5:00 PM EST on April 22, 2025, with the contract period running from June 1, 2025, to May 31, 2026.
The solicitation has no specific set-aside designation and is open to all qualifying pediatric vaccine manufacturers. The contract allows for vaccine order quantities ranging from a minimum of 100 doses to a maximum of 15 million doses, with each dose subject to a federal excise tax of $0.75. Delivery will be to CDC distribution centers located in Olive Branch, MS, Aurora, CO, and Clermont, KY, with options for both bulk and direct ship delivery. The goal is to obtain vaccines at prices below commercial market rates using VFC funds and Section 317 vaccine purchase funds. Awardees may also have the opportunity to purchase additional vaccine quantities using state and local funds. The place of performance is designated as Chamblee, GA 30341, with the potential for nationwide vaccine distribution through the CDC's established distribution network.
Notice text
The Centers for Disease Control and Prevention (CDC) awards contracts to the manufacturers of pediatric vaccines for the purchase of standard commercial pediatric vaccines.
CDC seeks to award contracts for all U.S-licensed or authorized COVID-19 brands with a pediatric indication. Vaccines are one of the most cost-effective ways to prevent disease and reduce healthcare costs. The Vaccine for Children (VFC) program, established pursuant to Section 13631 of the Omnibus Budget Reconciliation Act of 1993 (OBRA ’93), guarantees federal support for the purchase and supply of sufficient quantities of vaccine to the States to cover a defined group of children. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage. Children (18 years-of-age or younger) who qualify for immunization through the VFC purchase program include those who are (1) Medicaid-eligible, (2) without health insurance, (3) American Indian/Alaska native (as defined in Subsection (h)(3) of the OBRA ’93), or (4) children with health insurance, which does not cover the cost of vaccines, if they receive their immunizations at a Federally-qualified health center or rural health clinic (as defined by the Social Security Act). Health care providers who agree to certain requirements are eligible through the States to receive free vaccine through this VFC purchase program.
The establishment of these contracts provides an opportunity to utilize VFC funds and Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial marketplace. In addition, awardees may opt to purchase additional quantities of vaccine under any resulting contract to provide immunizations for children who are not federally vaccine-eligible children using state and local funds.
Offerors for this requirement must be manufacturers of pediatric vaccines in accordance with 42 U.S.C. § 1396s. The term "manufacturer" means any corporation, organization, or institution, whether public or private (including Federal, State, and local departments, agencies, and instrumentalities), which manufactures, imports, processes, or distributes under its label any pediatric vaccine. The term "manufacture" means to manufacture, import, process, or distribute a vaccine.
Files
| File | Type | Posted |
|---|---|---|
| Attachment 2 - ADR Agreement.docx | DOCX document | |
| Solicitation - 75D30125R00116 - COVID 19 Pediatric.pdf | ||
| Solicitation - 75D30125R00116 - COVID 19 Pediatric.docx | DOCX document | |
| Attachment 1 - Vaccine Order Limitation Chart.docx | DOCX document |
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity